Atea Pharmaceuticals, Inc. (AVIR) stock
AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.96−0.16 (-3.88%)
Close on Nov 17, 2026Market cap $317.61MP/E –Yield –
Atea Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Atea Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$152.07M. For fiscal 2025 it was -$132.03M. The highest annual figure on record is $296.73M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$132.03M | – |
| FY2024 | Dec 31, 2024 | -$135.50M | – |
| FY2023 | Dec 31, 2023 | -$85.40M | – |
| FY2022 | Dec 31, 2022 | -$120.98M | – |
| FY2021 | Dec 31, 2021 | -$87.01M | -129.3% |
| FY2020 | Dec 31, 2020 | $296.73M | – |
| FY2019 | Dec 31, 2019 | -$12.83M | – |
| FY2018 | Dec 31, 2018 | -$7.91M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$37.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$46.39M | – |
| Q4 FY2025 | Dec 31, 2025 | -$28.22M | – |
| Q3 FY2025 | Sep 30, 2025 | -$40.38M | – |
| Q2 FY2025 | Jun 30, 2025 | -$32.87M | – |
| Q1 FY2025 | Mar 31, 2025 | -$30.56M | – |
| Q4 FY2024 | Dec 31, 2024 | -$30.40M | – |
| Q3 FY2024 | Sep 30, 2024 | -$23.04M | – |
| Q2 FY2024 | Jun 30, 2024 | -$42.20M | – |
| Q1 FY2024 | Mar 31, 2024 | -$39.87M | – |
| Q4 FY2023 | Dec 31, 2023 | -$21.83M | – |
| Q3 FY2023 | Sep 30, 2023 | -$17.59M | – |
| Q2 FY2023 | Jun 30, 2023 | -$16.12M | – |
| Q1 FY2023 | Mar 31, 2023 | -$29.85M | – |
| Q4 FY2022 | Dec 31, 2022 | -$21.55M | – |
| Q3 FY2022 | Sep 30, 2022 | -$21.24M | -194.0% |
| Q2 FY2022 | Jun 30, 2022 | -$19.19M | – |
| Q1 FY2022 | Mar 31, 2022 | -$59.01M | – |
| Q4 FY2021 | Dec 31, 2021 | -$75.42M | -123.7% |
| Q3 FY2021 | Sep 30, 2021 | $22.60M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.35M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.84M | – |
| Q4 FY2020 | Dec 31, 2020 | $318.52M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.48M | – |
| Q2 FY2020 | Jun 30, 2020 | -$7.80M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.51M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.94M | – |
See a number that looks wrong?